WO2018194116A1 - 脂質吸収促進剤 - Google Patents

脂質吸収促進剤 Download PDF

Info

Publication number
WO2018194116A1
WO2018194116A1 PCT/JP2018/016090 JP2018016090W WO2018194116A1 WO 2018194116 A1 WO2018194116 A1 WO 2018194116A1 JP 2018016090 W JP2018016090 W JP 2018016090W WO 2018194116 A1 WO2018194116 A1 WO 2018194116A1
Authority
WO
WIPO (PCT)
Prior art keywords
palmitic acid
fat
fat absorption
fats
promoting
Prior art date
Application number
PCT/JP2018/016090
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
有希 木村
昌士 長田
Original Assignee
株式会社明治
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 株式会社明治 filed Critical 株式会社明治
Publication of WO2018194116A1 publication Critical patent/WO2018194116A1/ja

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism

Definitions

  • the present invention relates to a fat absorption promoter.
  • Fatty acid which is a component of fat, is one of the main energy sources for humans and is very important especially for infants.
  • Fatty acids are combined with triglycerides to form fats, and after ingestion, they are hydrolyzed by pancreatic lipase in the human body, and the fatty acids bound to the ⁇ - and ⁇ ′-positions of triglycerides become free fatty acids and are absorbed.
  • the absorption of free fatty acid differs depending on the type of fatty acid, the binding site with triglyceride, and the like, and various studies have been conducted so far.
  • JP-A-2002-180082 discloses fats and oils in which an omega-3 fatty acid such as docosahexaenoic acid or eicosapentaenoic acid is bonded to the 2-position, and a medium-chain fatty acid is bonded to the 1,3-position.
  • the fats and oils are described as having good absorption of omega-3 fatty acids.
  • JP-T-2006-521368 Patent Document 2 describes a lipid improving agent comprising a triglyceride in which a highly unsaturated fatty acid is bonded to the 2-position of the triglyceride.
  • an object of the present invention is to provide a fat absorption enhancer that can be safely and easily ingested, while obtaining a sufficient fat absorption promoting effect.
  • the present inventors focused on palmitic acid among fatty acids, and particularly focused on palmitic acid that binds to the ⁇ -position of glycerides (hereinafter also referred to as ⁇ -palmitic acid).
  • ⁇ -palmitic acid glycerides
  • the characteristics were examined again in detail.
  • the present inventors have found that fats and oils containing ⁇ -palmitic acid at a high concentration have an excellent fat absorption promoting action, thereby completing the present invention.
  • a fat absorption promoter and a composition for promoting fat absorption comprising an oil and fat containing ⁇ -position palmitic acid as an active ingredient.
  • a ratio of palmitic acid at the ⁇ -position to total palmitic acid is 54% or more and less than 98%.
  • the present invention also includes the following inventions.
  • a method for promoting fat absorption comprising a step of ingesting or administering a fat and oil containing ⁇ -position palmitic acid to a mammal.
  • Fats and oils containing ⁇ -palmitic acid for use in the production of a composition for promoting fat absorption, for use in the production of a fat absorption promoter, or for use in promoting fat absorption .
  • a fat absorption accelerator having an excellent effect can be provided.
  • ⁇ -palmitic acid which is an active ingredient of the present invention, has a long dietary experience, and its safety is well supported.
  • the composition containing the fat absorption promoter of the present invention is excellent in digestion and absorption of fat, and is very useful, for example, for nutritional supplementation and nutritional improvement of infants and the elderly.
  • the present invention is a fat absorption promoter comprising fats and oils containing ⁇ -position palmitic acid as an active ingredient.
  • fat absorption is used to mean “lipid absorption”.
  • the ⁇ -palmitic acid constituting the active ingredient of the present invention is a substance in which palmitic acid is bonded to the ⁇ -position of glyceride, and refers to all the same compounds in the chemical formula.
  • ⁇ -palmitic acid may be a pure product or a mixture with other substances.
  • a raw material whose ⁇ -palmitic acid is measured by a known measurement method and its presence is confirmed may be used as it is.
  • a typical raw material (mixture) rich in ⁇ -position palmitic acid is lard, which can also be used.
  • a commercially available product of ⁇ -position palmitic acid may be purchased and appropriately mixed with other raw materials.
  • the ratio of palmitic acid at the ⁇ -position of triglyceride to the total palmitic acid of the fat and oil is 65% to 75% is preferable, 67% to 73% is more preferable, and 68% to 72% is particularly preferable.
  • the ratio is less than 65%, the effect as the fat absorption promoter of the present invention cannot be sufficiently obtained.
  • the said ratio exceeds 75%, it cannot manufacture stably enough.
  • the fat absorption promoter of the present invention exerts its function by ingestion or oral administration to mammals including humans. In the present invention, intake by eating and drinking is preferable.
  • the present invention relates to the use of fats and oils containing ⁇ -palmitic acid for producing a composition for promoting fat absorption, for producing a fat absorption promoter, or for promoting fat absorption. is there.
  • the present invention is also a method for promoting fat absorption, characterized by using an oil containing ⁇ -palmitic acid.
  • the present invention relates to ⁇ -palmitin for use in the manufacture of a composition for promoting fat absorption, for use in the manufacture of a fat absorption enhancer, or for use in promoting fat absorption. It is also an oil and fat containing acid.
  • non-therapeutic means that it does not include an act of operating, treating or diagnosing a human (ie, a medical act on a human). Specifically, a doctor or a person who has received instructions from a doctor It means not including methods for performing surgery, treatment or diagnosis on humans.
  • the fat absorption promoter and the composition for promoting fat absorption of the present invention can be provided in the form of pharmaceuticals (for example, pharmaceutical compositions), quasi drugs, foods, feeds, etc., and should be carried out according to the following description. Can do.
  • the present invention may be taken or administered alone, or may be taken or administered in combination with a normal meal or the like.
  • the fat absorption enhancer of the present invention that is, fats and oils containing ⁇ -palmitic acid are particularly excellent in digestion and absorption of fats as compared with conventional fat and oil compositions, so that especially nutritional supplementation for infants and toddlers. It is suitable for improving nutritional status.
  • infants includes infants and infants, and more specifically includes infants, infants and newborns, and more specifically includes infants, infants, newborns, premature infants, preterm infants and low birth weight infants.
  • infant refers to a child in the infancy, and the term “infancy” means a period in which milk such as breast milk is a main nutritional source.
  • infants generally refer to children in pre-school age.
  • a newborn refers to a child in the neonatal period, and the neonatal period means a period just after birth. In the case of a human, the neonatal period usually falls within 4 weeks after birth.
  • a composition capable of promoting fat absorption by combining fat and oil containing ⁇ -palmitic acid with other raw materials ie, a composition for promoting fat absorption
  • other raw materials ie, a composition for promoting fat absorption
  • infant formula a composition capable of promoting fat absorption by combining fat and oil containing ⁇ -palmitic acid with other raw materials
  • infant formula a composition for promoting fat absorption
  • infant formula use as infant formula is particularly preferred.
  • the intake and dose of the fat absorption promoter of the present invention can be appropriately set in consideration of various factors such as the intake subject and the administration subject's nutritional status, age, weight, and symptoms.
  • the intake and dose of the fat absorption promoter of the present invention are not particularly limited.
  • the weight per unit package of the fat absorption promoter of the present invention is not particularly limited.
  • the weight is preferably in the range of 10 g to 500 g, and preferably in the range of 25 g to 250 g. More preferably, it is most preferably in the range of 50 g or more and 200 g or less.
  • the unit packaging is not limited to unit packaging per bag, box, or container, but may be unit packaging per one time included therein or unit packaging per day. It should be noted that a plurality of days, for example, a package suitable for intake and administration for one week, or a package including a plurality of individual packages may be used.
  • Example 1 The effect of the difference in the ⁇ -position binding ratio of palmitic acid on the palmitic acid absorption rate was examined.
  • Groups of fats and oils having a low ⁇ -position binding ratio of palmitic acid, medium fats and oils, and high fats were set as Comparative Example 1, Comparative Example 2, and Example 1, respectively.
  • Table 1 shows the composition of the feed consumed by each group.
  • the ⁇ -position binding ratio of palmitic acid in the sample taken by each group was adjusted by adjusting the composition of “sample fat” shown in Table 1.
  • Table 2 shows the composition of main fatty acids and the ⁇ -position binding ratio of palmitic acid in each group.
  • the “ ⁇ -position binding ratio” of palmitic acid means the ratio (mass ratio) of palmitic acid binding to the ⁇ -position of triglyceride with respect to the total amount of palmitic acid.
  • the collected feces were freeze-dried, pulverized, and lipid extraction was performed by the method of Jeejeebhoy et al. (Clin. Biochem., 1970).
  • the extracted lipid was subjected to fatty acid analysis by the GC method and total lipid content analysis by the gravimetric method.
  • the amount of palmitic acid excreted in feces was significantly lower in Example 1 than in Comparative Example 1 and Comparative Example 2 in spite of no significant difference in the amount of fatty acid ingested (FIG. 1).
  • the amount of total lipids in feces was also significantly reduced in Example 1 (FIG. 2).
  • Example 2 The following experiment was conducted for the purpose of simulating the characteristics during digestion after fat intake.
  • the fats and oils of Example 2 and Comparative Example 3 were prepared.
  • the main fatty acid compositions of Example 2 and Comparative Example 3 are shown in Table 4.
  • the major difference between the fats and oils of the examples and the comparative examples is only the binding ratio of palmitic acid to the ⁇ -position, and the other major fatty acid compositions are almost the same.
  • an artificial digestion reaction solution was prepared with the composition shown in Table 5.
  • Concentrations of components in the artificial digestion reaction solution after preparation were 20 mg / mL for bile acids, 2.4 mg / mL for lipase, 19 mM for calcium chloride, 150 mM for sodium chloride, and 2.5% for fats and oils.
  • As the lipase “Lipase from porcine pancreas (Type II)” (manufactured by Sigma-Aldrich, Cat. No. L3126) was used.
  • Example 2 and Comparative Example 3 About 40 mL of the above artificial digestion reaction solution was taken for each of Example 2 and Comparative Example 3 in a 50 mL glass beaker and allowed to react for 2 hours in a hot water bath set at 37 ° C. while stirring with a magnetic stirrer. It was. During the reaction, 0.5N sodium hydroxide solution was added dropwise using an automatic titrator so that the pH was always 7.0. The particle size and zeta potential of the reaction solution were measured before and after the reaction. The particle size of the reaction solution was measured by a laser diffraction / scattering particle size distribution analyzer (LS13320, manufactured by Beckman Coulter, Inc.). The zeta potential was measured by a zeta potential measurement system (ELS-Z1 manufactured by Otsuka Electronics Co., Ltd.).
  • ELS-Z1 laser diffraction / scattering particle size distribution analyzer
  • Example 2 The measurement results are shown in Table 6.
  • the particle size of the artificial digestion reaction solution after the digestion reaction increased.
  • the value of the particle size itself was smaller in Example 2, and from this, it was considered that Example 2 had better absorbability.
  • the absolute value of the zeta potential increased after the digestion reaction in both Example 2 and Comparative Example 3.
  • the amount of increase in Example 2 was smaller, and the absolute value itself was smaller in Example 2 than in Comparative Example 3.
  • the zeta potential is an index of the surface charge of the particles, and the larger the absolute value, the more repulsive the particles are, and it can be said that they are in a stable state without agglomeration.
  • fats and oils containing a high concentration of palmitic acid with a high binding ratio to the ⁇ -position are superior in fat digestibility compared to fats and oils containing a low concentration of palmitic acid with a high binding ratio to the ⁇ -position.
  • a composition using an oil containing a high concentration of palmitic acid having a high binding ratio to the ⁇ -position is superior in digestibility and absorption of fat compared to a composition containing a conventional oil, for example, for infants and the elderly. It is considered to be very useful for nutrition and nutritional improvement.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Polymers & Plastics (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nutrition Science (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Mycology (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Edible Oils And Fats (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PCT/JP2018/016090 2017-04-20 2018-04-19 脂質吸収促進剤 WO2018194116A1 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2017083323A JP2018177734A (ja) 2017-04-20 2017-04-20 脂質吸収促進剤
JP2017-083323 2017-04-20

Publications (1)

Publication Number Publication Date
WO2018194116A1 true WO2018194116A1 (ja) 2018-10-25

Family

ID=63855961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2018/016090 WO2018194116A1 (ja) 2017-04-20 2018-04-19 脂質吸収促進剤

Country Status (3)

Country Link
JP (1) JP2018177734A (enrdf_load_stackoverflow)
TW (1) TW201900038A (enrdf_load_stackoverflow)
WO (1) WO2018194116A1 (enrdf_load_stackoverflow)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023069411A (ja) * 2021-11-05 2023-05-18 太陽油脂株式会社 脂溶性微量成分の吸収促進剤

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015091228A (ja) * 2013-10-02 2015-05-14 株式会社カネカ 油脂組成物
JP2015109808A (ja) * 2012-03-29 2015-06-18 株式会社カネカ 油脂組成物
JP2016202001A (ja) * 2013-10-02 2016-12-08 株式会社カネカ 油脂組成物

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015109808A (ja) * 2012-03-29 2015-06-18 株式会社カネカ 油脂組成物
JP2015091228A (ja) * 2013-10-02 2015-05-14 株式会社カネカ 油脂組成物
JP2016202001A (ja) * 2013-10-02 2016-12-08 株式会社カネカ 油脂組成物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
KATAOKA, NAOKI: "Study on triglyceride structure of milk powder and fat utilization of infants", JAPAN PEDIATRIC SOCIETY, vol. 83, no. 9, 1979, pages 1130 - 1145 *

Also Published As

Publication number Publication date
JP2018177734A (ja) 2018-11-15
TW201900038A (zh) 2019-01-01

Similar Documents

Publication Publication Date Title
CN103687500B (zh) 专门设计的脂质组分的代谢印迹效应
DK2836084T3 (en) FOOD COMPOSITION
TWI332399B (en) Nutritional composition for controlling blood sugar level
CN103384478B (zh) 降低婴儿、幼儿或儿童的坏死性小肠结肠炎、腹痛和短肠综合征的发病率的方法
EP2753190B1 (en) Use of infant formula with cholesterol
EP3016529B1 (en) New prophylactic use for prevention of infections
JP6609555B2 (ja) 脳機能改善剤、及び認知機能障害の予防または治療剤
Bourlieu-Lacanal et al. Towards infant formula biomimetic of human milk structure and digestive behaviour
CN107223971A (zh) 具有大的脂质小球尺寸的营养组合物
EA027684B1 (ru) Твердая композиция, содержащая железо, для применения при железодефицитных состояниях
TW201039759A (en) Reduction of risk of obesity
HK1219206A1 (zh) 增强dha和其它脂溶性营养物的生物利用度的方法
TW201236578A (en) Nutritional products comprising beta-hydroxy-beta-methylbutyrate
EP2753191B1 (en) Use of infant formula with large lipid globules
AU2016221293C1 (en) Oil blends, processes for the preparation thereof and their use in formulas
JP4034370B2 (ja) 脳機能改善剤及び栄養組成物
TW201032734A (en) Nutritional composition for infants
WO2018194116A1 (ja) 脂質吸収促進剤
CN1802102A (zh) 用于预防和/或治疗脓毒症的肠内组合物
RU2485808C2 (ru) Композиция с фитостеролами повышенной биологической доступности
JP2012036112A (ja) 生物学的利用能（バイオアベイラビリティー）を向上させる製品の製造方法および製品
JPH10262607A (ja) 乳幼児用栄養組成物
CN114554873A (zh) 包含乳磷脂和蛋磷脂的营养组合物
JP4307475B2 (ja) 乳幼児用栄養組成物
HK40068081A (en) A nutritional composition

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18788219

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18788219

Country of ref document: EP

Kind code of ref document: A1